Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 18 Oct 2023 – 20 Aug 2026, limited by UTI Innovation Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | UTI Innovation Fund | Nifty 500 |
|---|---|---|
| 18 Oct 2023 | ₹100.00 | ₹100.00 |
| 12 Jan 2024 | ₹108.81 | ₹113.85 |
| 08 Apr 2024 | ₹109.57 | ₹120.04 |
| 03 Jul 2024 | ₹116.92 | ₹131.75 |
| 28 Sep 2024 | ₹129.16 | ₹141.20 |
| 23 Dec 2024 | ₹123.66 | ₹129.22 |
| 20 Mar 2025 | ₹102.76 | ₹121.48 |
| 14 Jun 2025 | ₹113.92 | ₹132.07 |
| 08 Sep 2025 | ₹117.90 | ₹131.91 |
| 04 Dec 2025 | ₹115.63 | ₹136.88 |
| 28 Feb 2026 | ₹97.46 | ₹133.57 |
| 26 May 2026 | ₹107.44 | ₹132.02 |
| 20 Aug 2026 | ₹119.23 | ₹135.57 |
| Metric | UTI · Regular NAV ₹11.94 Very High risk ★☆☆☆☆ 1Y | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +0.58% | +5.83% | |
| — | +15.63% | |
| — | +13.23% | |
| — | +13.85% | |
| +6.39% | +12.26% | |
| +5.27% | — | |
| — | +15.60% | |
| — | +14.52% | |
| — | +13.74% | |
| Risk | ||
| 18.13% | 15.62% | |
| -0.33 | 0.43 | |
| -0.45 | 0.59 | |
| -32.94% | -23.65% | |
| Nifty 500 | — | |
| -4.90% | +3.42% | |
| 1.06 | 0.95 | |
| 82.4% | 105.9% | |
| 105.7% | 93.6% | |
| 2.35% | 2.39% | |
| ₹732.35Cr | ₹1,161Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 25% | 45% | |
| Nitin Jain | — | |
| 18 Oct 2023 | — | |
| 31 | — | |
| 56.4% | — | |
| 2.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.